Augtyro (repotrectinib), which first got a green light from the FDA as a treatment for ROS1-positive non-small-cell lung cancer (NSCLC) last November, has now had its label extended to include all ...

FDA approval, and medication availability; and not necessarily guided by evidence-based practice. For example, some obstetric providers choose to use misoprostol off-label because it is stable at ...